Q-omics provides the consensus-scored LINC01826 profile across patient tissues and cancer cell-line models. LINC01826 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LINC01826 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, LINC01826 RNA expression shows 6,256 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, BRCA, and STAD as cancer lineages where LINC01826 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01826 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01826 survival associations across molecular data types. LINC01826 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01826 RNA expression–survival associations across cancer types. High LINC01826 expression shows unfavorable associations in BLCA, THYM, MESO, OV and ESCA, but favorable associations in SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LINC01826 RNA expression.
This table summarizes LINC01826 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01826. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01826 shows higher tumor expression in BRCA and KIRC. The BRCA box plot shows higher LINC01826 RNA expression in tumor versus normal tissue (log2 FC = +0.016, t-test p = .038).
This table shows molecular features associated with LINC01826 in patient tissues and cancer cell lines. In patient samples, LINC01826 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
